Recursion has stumbled through an early test of its tech-enabled approach to drug discovery, reporting a hit on its phase 2 primary endpoint of safety and tolerability but failing to wow on the ...

For years, drug developers that apply artificial intelligence (AI) have touted the benefits of the technology—the prospect of speedier development of new treatments at lower cost, thus reducing the ...